Company Overview

​

GrayMatters Health (GMH) is a health technology company developing and marketing an interventional psychiatry suite powered by proprietary fMRI-Informed biomarkers. A growing community of psychiatry clinics across the US is building Prism programs for personalized patient care. The expert team in the US is leading commercial growth, market access, medical strategy and training programs.  

​

GMH is the first company to develop digital brain region specific biomarkers for mental health. While medical biomarkers usually measure tissue to assess disease. The EFP (EEG-fMRI-Pattern) measures brain activity associated with mental health disorders. These biomarkers were developed by harnessing advanced machine learning to register fMRI data to readily accessible EEG. This innovation brings the power of evidence-based, precision self-neuromodulation to any psychiatry clinic. GMH is collaborating with key medical institutions to research and evaluate additional EFP biomarkers to expand the clinical portfolio. 

​

Founded in 2018 by Oded Kraft, Rani Cohen and Shai Attia, GMH is on a mission to connect mental health disorders to their underlying brain mechanisms to improve patient care and outcomes. The company’s patented core technology was invented by Professor Talma Hendler, MD, PhD and her team at Tel Aviv University, with further development by GMH’s talented team of engineers. 

 

The name, GrayMatters Health, is a play on words highlighting the importance of the gray matter of the brain as well as the significance of the knowledge and experience that comes with the gray hairs of age. The company was recognized in 2024 as a Most Innovative Company by Fast Magazine and in 2023, received the Prix Galien USA Best Startup Award. 

​